Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Preferred Dividend Payments (2016 - 2019)

Historic Preferred Dividend Payments for Outlook Therapeutics (OTLK) over the last 5 years, with Q4 2019 value amounting to $166133.0.

  • Outlook Therapeutics' Preferred Dividend Payments rose 1038.15% to $166133.0 in Q4 2019 from the same period last year, while for Jun 2020 it was $328214.0, marking a year-over-year decrease of 4763.06%. This contributed to the annual value of $166133.0 for FY2020, which is 7341.82% down from last year.
  • Outlook Therapeutics' Preferred Dividend Payments amounted to $166133.0 in Q4 2019, which was up 1038.15% from $162081.0 recorded in Q3 2019.
  • In the past 5 years, Outlook Therapeutics' Preferred Dividend Payments ranged from a high of $1.1 million in Q3 2015 and a low of $150508.0 during Q4 2018
  • Moreover, its 5-year median value for Preferred Dividend Payments was $493207.0 (2016), whereas its average is $559569.0.
  • Over the last 5 years, Outlook Therapeutics' Preferred Dividend Payments had its largest YoY gain of 1038.15% in 2019, and its largest YoY loss of 7577.0% in 2019.
  • Outlook Therapeutics' Preferred Dividend Payments (Quarter) stood at $939539.0 in 2015, then plummeted by 47.51% to $493207.0 in 2016, then fell by 8.6% to $450801.0 in 2017, then crashed by 66.61% to $150508.0 in 2018, then rose by 10.38% to $166133.0 in 2019.
  • Its Preferred Dividend Payments was $166133.0 in Q4 2019, compared to $162081.0 in Q3 2019 and $158128.0 in Q2 2019.